Exchange: NASDAQ·Updated 08:57 AM EDT

PPBT News

News
all
press releases
Crude Oil Moves Higher; US Factory Orders Rise In July
U.S. stocks rose mid-session, led by materials; factory orders beat estimates. Linkhome, Purple Biotech and GitLab surged, while Tscan and Credo fell.read more...
Benzinga
More News
Purple Biotech’s Patent Win Adds Armor to a Bigger Oncology Bet
Purple Biotech (NASDAQ:PPBT) just strengthened one of the most important pieces of its oncology strategy: the intellectual-property foundation behind CAPTN-3, its modular platform for conditionally activated tri-specific antibodies designed to attack tumors while potentially limiting systemic immune toxicity.
24-7 Market News
Purple Biotech CEO Gil Efron To Step Down For Health Reasons
(RTTNews) - Purple Biotech Ltd. (PPBT), a clinical-stage pharmaceutical company, Friday announced that its Chief Executive Officer, Gil Efron will step down from his role in August, due to health...
Nasdaq News: Markets
Purple Biotech Shares Soar 92% On Breakthrough For Experimental Cancer Drug
Stocktwits
Purple Biotech's Shrinking Losses Keep Retail Sentiment In The Green, But Other Pressures Loom
As of Dec. 31, 2024, Purple Biotech had $8.2 million in cash and short-term deposits, which it expects will be sufficient to fund operations into mid-2026.
Stocktwits
News Movers: Yesterday’s Hottest News That Could Move the Needle Today
Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks
Stocktwits Contributor
Purple Biotech Stock Hits Nearly 2-Month High On Cancer Drug Trial Success: Retail Thrilled
CM24 targets CEACAM1, a multi-functional membrane glycoprotein that plays a critical role in tumor invasiveness, metastasis, and immune evasion.
Stocktwits

Advertisement|Remove ads.